HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: clinchem.2006.068205v1 52/12/2250    most recent Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Tan, A. Articles by Dobrovic, A. Search for Related Content PubMed PubMed Citation Articles by Tan, A. Articles by Dobrovic, A. Related Collections Molecular Diagnostics and Genetics Cancer Diagnostics (since 2002)

Sensitive Detection of KIT D816V in Patients with Mastocytosis

¹ Departments of Pathology and ² Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
³ Departments of Medicine and ⁴ Pathology, University of Melbourne, VIC, Australia.
⁵ Medical Department, Novartis Pharmaceuticals, North Ryde, NSW, Australia.

^aAddress correspondence to this author at: Department of Pathology, Peter MacCallum Cancer Centre, Locked Bag No. 1 A’Beckett Street, Melbourne, Victoria, 8006, Australia. Fax 61-3-9656-1460; email angela.tan{at}petermac.org.

Background: The 2447 A>T pathogenic variation at codon 816 of exon 17 (D816V) in the KIT gene, occurring in systemic mastocytosis (SM), leads to constitutive activation of tyrosine kinase activity and confers resistance to the tyrosine kinase inhibitor imatinib mesylate. Thus detection of this variation in SM patients is important for determining treatment strategy, but because the population of malignant cells carrying this variation is often small relative to the normal cell population, standard molecular detection methods can be unsuccessful.

Methods: We developed 2 methods for detection of KIT D816V in SM patients. The first uses enriched sequencing of mutant alleles (ESMA) after BsmAI restriction enzyme digestion, and the second uses an allele-specific competitive blocker PCR (ACB-PCR) assay. We used these methods to assess 26 patients undergoing evaluation for SM, 13 of whom had SM meeting WHO classification criteria (before variation testing), and we compared the results with those obtained by direct sequencing.

Results: The sensitivities of the ESMA and the ACB-PCR assays were 1% and 0.1%, respectively. According to the ACB-PCR assay results, 65% (17/26) of patients were positive for D816V. Of the 17 positive cases, only 23.5% (4/17) were detected by direct sequencing. ESMA detected 2 additional exon 17 pathogenic variations, D816Y and D816N, but detected only 12 (70.5%) of the 17 D816V-positive cases. Overall, 100% (15/15) of the WHO-classified SM cases were codon 816 pathogenic variation positive.

Conclusion: These findings demonstrate that the ACB-PCR assay combined with ESMA is a rapid and highly sensitive approach for detection of KIT D816V in SM patients.

The following articles in journals at HighWire Press have cited this article:

				J A Schumacher, K S J Elenitoba-Johnson, and M S Lim Detection of the c-kit D816V mutation in systemic mastocytosis by allele-specific PCR J. Clin. Pathol., January 1, 2008; 61(1): 109 - 114. [Abstract] [Full Text] [PDF]